FULL SUPPLEMENT: TIRBANIBULIN 1% OINTMENT FOR ACTINIC KERATOSIS LESS PAIN, MORE GAIN

October 2021 | Volume 20 | Issue 10 | Department | s3s | Copyright © October 2021


Published online September 30, 2021

Abstract
Topical agents for actinic keratosis (AK), along with cryotherapy and phototherapy, are the most commonly used therapies for areas of skin with multiple AKs. Multiple options for the topical treatment of AK exist; newer therapies aim to balance efficacy with an acceptable safety and tolerability profile for the patient. To describe the safety and tolerability of FDA-approved topical agents for the treatment of AK, a systematic review of phase III clinical trials of topical agents for AK available on PubMed and clinicaltrials.gov was conducted on January 10th, 2021.